ANMCX | SFCCX | ANMCX / SFCCX | |
Total Expense Ratio | 1.50 | 1.55 | 97% |
Annual Report Gross Expense Ratio | 1.50 | 1.61 | 93% |
Fund Existence | 23 years | 23 years | - |
Gain YTD | -0.513 | 0.294 | -174% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 1000 | 250% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 1.25B | 297M | 422% |
Annual Yield % from dividends | 1.78 | 1.51 | 118% |
Returns for 1 year | 0.86 | 1.82 | 47% |
Returns for 3 years | 5.46 | 4.89 | 112% |
Returns for 5 years | 4.48 | 0.46 | 983% |
Returns for 10 years | 4.09 | 0.28 | 1,441% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
COSNX | 11.32 | 0.10 | +0.89% |
Columbia Overseas Core Institutional | |||
PCBSX | 14.91 | 0.03 | +0.20% |
BlackRock Tactical Opportunities Service | |||
RNNEX | 56.65 | -0.06 | -0.11% |
American Funds New Economy R2E | |||
MSSLX | 8.27 | -0.06 | -0.72% |
Morgan Stanley Inst Inception L | |||
RYBOX | 49.98 | -1.02 | -2.00% |
Rydex Biotechnology A |